Russia's Moscow region to announce $50-million tender for supplies of vital drugs

30 May 2019

The authorities of Russia’s Moscow region plan to organize a tender for the supplies of certain vital drugs for the needs of local customers, according to the press-service of the government of the Moscow region.

The amount of the potential contract is estimated at almost $50 million, while under its conditions the potential investor should localize production within the Moscow region with the minimum investments of about 1 billion roubles ($15.5 million), reports The Pharma Letter’s local correspondent.

All construction works must be completed within two years after signing of the contract.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK